The holistic pathogenesis and management of EGPA remains elusive; however, discovering specific disease-driven routes (eg, IL-5 axis) and targeting their significant components represents a major breakthrough in understanding the disease and its treatment respectively. The gene discussed is IL5; the disease is eosinophilic granulomatosis with polyangiitis.